327 related articles for article (PubMed ID: 31238530)
1. Nuclear-Biased DUSP6 Expression is Associated with Cancer Spreading Including Brain Metastasis in Triple-Negative Breast Cancer.
Wu F; McCuaig RD; Sutton CR; Tan AHY; Jeelall Y; Bean EG; Dai J; Prasanna T; Batham J; Malik L; Yip D; Dahlstrom JE; Rao S
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31238530
[TBL] [Abstract][Full Text] [Related]
2. The identification of a TNBC liver metastasis gene signature by sequential CTC-xenograft modeling.
Vishnoi M; Liu NH; Yin W; Boral D; Scamardo A; Hong D; Marchetti D
Mol Oncol; 2019 Sep; 13(9):1913-1926. PubMed ID: 31216110
[TBL] [Abstract][Full Text] [Related]
3. Investigating circulating tumor cells and distant metastases in patient-derived orthotopic xenograft models of triple-negative breast cancer.
Ramani VC; Lemaire CA; Triboulet M; Casey KM; Heirich K; Renier C; Vilches-Moure JG; Gupta R; Razmara AM; Zhang H; Sledge GW; Sollier E; Jeffrey SS
Breast Cancer Res; 2019 Aug; 21(1):98. PubMed ID: 31462307
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients.
Agelaki S; Dragolia M; Markonanolaki H; Alkahtani S; Stournaras C; Georgoulias V; Kallergi G
Oncotarget; 2017 Jan; 8(3):5309-5322. PubMed ID: 28029660
[TBL] [Abstract][Full Text] [Related]
5. Soyasaponin Ag inhibits triple-negative breast cancer progression via targeting the DUSP6/MAPK signaling.
Huang S; Huang P; Wu H; Wang S; Liu G
Folia Histochem Cytobiol; 2021; 59(4):291-301. PubMed ID: 34970732
[TBL] [Abstract][Full Text] [Related]
6. Use of a multiplexed immunoassay (PRO Onc assay) to detect HER2 abnormalities in circulating tumor cells of women with HER2-negative metastatic breast cancer: lack of response to HER2-targeted therapy.
Hainsworth JD; Murphy PB; Alemar JR; Daniel BR; Young RR; Yardley DA
Breast Cancer Res Treat; 2016 Nov; 160(1):41-49. PubMed ID: 27632289
[TBL] [Abstract][Full Text] [Related]
7. Modulation of Mitochondrial ERβ Expression Inhibits Triple-Negative Breast Cancer Tumor Progression by Activating Mitochondrial Function.
Song IS; Jeong YJ; Jeong SH; Kim JE; Han J; Kim TH; Jang SW
Cell Physiol Biochem; 2019; 52(3):468-485. PubMed ID: 30873822
[TBL] [Abstract][Full Text] [Related]
8. p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer.
Powell E; Shao J; Yuan Y; Chen HC; Cai S; Echeverria GV; Mistry N; Decker KF; Schlosberg C; Do KA; Edwards JR; Liang H; Piwnica-Worms D; Piwnica-Worms H
Breast Cancer Res; 2016 Jan; 18(1):13. PubMed ID: 26818199
[TBL] [Abstract][Full Text] [Related]
9. Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage I-III Triple-Negative Breast Cancer.
Hall C; Karhade M; Laubacher B; Anderson A; Kuerer H; DeSynder S; Lucci A
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S552-8. PubMed ID: 25968619
[TBL] [Abstract][Full Text] [Related]
10. Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer.
Gagliardi M; Pitner MK; Park J; Xie X; Saso H; Larson RA; Sammons RM; Chen H; Wei C; Masuda H; Chauhan G; Kondo K; Tripathy D; Ueno NT; Dalby KN; Debeb BG; Bartholomeusz C
Sci Rep; 2020 May; 10(1):8537. PubMed ID: 32444778
[TBL] [Abstract][Full Text] [Related]
11. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
Kim S; Lee J; Jeon M; Lee JE; Nam SJ
Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
[TBL] [Abstract][Full Text] [Related]
12. Absence of integrin α3β1 promotes the progression of HER2-driven breast cancer in vivo.
Ramovs V; Secades P; Song JY; Thijssen B; Kreft M; Sonnenberg A
Breast Cancer Res; 2019 May; 21(1):63. PubMed ID: 31101121
[TBL] [Abstract][Full Text] [Related]
13. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer.
Wang J; Song C; Tang H; Zhang C; Tang J; Li X; Chen B; Xie X
Breast Cancer Res; 2017 Jun; 19(1):72. PubMed ID: 28629464
[TBL] [Abstract][Full Text] [Related]
14. CTCs-derived xenograft development in a triple negative breast cancer case.
Pereira-Veiga T; Abreu M; Robledo D; Matias-Guiu X; Santacana M; Sánchez L; Cueva J; Palacios P; Abdulkader I; López-López R; Muinelo-Romay L; Costa C
Int J Cancer; 2019 May; 144(9):2254-2265. PubMed ID: 30450632
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of circulating tumour cells identifies predictive markers for outcome in primary, triple-negative breast cancer patients.
Bittner AK; Keup C; Hoffmann O; Hauch S; Kimmig R; Kasimir-Bauer S
J Cell Mol Med; 2020 Aug; 24(15):8405-8416. PubMed ID: 32558176
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
17. CIP4 promotes metastasis in triple-negative breast cancer and is associated with poor patient prognosis.
Cerqueira OL; Truesdell P; Baldassarre T; Vilella-Arias SA; Watt K; Meens J; Chander H; Osório CA; Soares FA; Reis EM; Craig AW
Oncotarget; 2015 Apr; 6(11):9397-408. PubMed ID: 25823823
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer.
Agelaki S; Kalykaki A; Markomanolaki H; Papadaki MA; Kallergi G; Hatzidaki D; Kalbakis K; Mavroudis D; Georgoulias V
PLoS One; 2015; 10(6):e0123683. PubMed ID: 26083256
[TBL] [Abstract][Full Text] [Related]
19. CD133 expression in circulating tumor cells from breast cancer patients: potential role in resistance to chemotherapy.
Nadal R; Ortega FG; Salido M; Lorente JA; Rodríguez-Rivera M; Delgado-Rodríguez M; Macià M; Fernández A; Corominas JM; García-Puche JL; Sánchez-Rovira P; Solé F; Serrano MJ
Int J Cancer; 2013 Nov; 133(10):2398-407. PubMed ID: 23661576
[TBL] [Abstract][Full Text] [Related]
20. MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis.
Dutta P; Sarkissyan M; Paico K; Wu Y; Vadgama JV
Breast Cancer Res Treat; 2018 Aug; 170(3):477-486. PubMed ID: 29594759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
